Small Cell Lung Cancer Treatment Professional Information

General Information

Without treatment, small cell carcinoma of the lung has the most aggressive clinical course of any type of pulmonary tumor, with median survival from diagnosis of only 2 to 4 months. Compared with other cell types of lung cancer, small cell carcinoma has a greater tendency to be widely disseminated by the time of diagnosis, but is much more responsive to chemotherapy and irradiation.

Because of its propensity for distant metastases, localized forms of treatment, such as surgical resection or radiation therapy, rarely produce long-term survival.¹ With incorporation of current chemotherapy regimens into the treatment program, however, survival is unequivocally prolonged, with at least a 4- to 5-fold improvement in median survival compared with patients who are given no therapy. Furthermore, about 10% of the total population of patients remain free of disease over two years from the start of therapy, the time period during which most relapses occur. However, even these patients are at risk of dying from lung cancer (both small and non-small cell types).² The overall survival at 5 years is 5% to 10%.^2-4

At the time of diagnosis, approximately 40% of patients with small cell carcinoma will have tumor confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes. These patients are designated as having limited stage disease, and most 2-year disease-free survivors come from this group. In limited stage disease, median survival of 16 to 24 months with current forms of treatment can reasonably be expected.^5-7 A small proportion of patients with limited stage disease may benefit from surgery with or without adjuvant chemotherapy; these patients have an even better prognosis. Patients with tumor that has spread beyond the supraclavicular areas are said to have extensive stage disease and have a worse prognosis than patients with limited stage. Median survival of 6 to 12 months is reported with currently available therapy, but long-term disease-free survival is rare.

The pretreatment prognostic factors which consistently predict for prolonged survival include good performance status, female gender, and limited stage disease.^3,8,9 Patients with involvement of the central nervous system or liver at the time of diagnosis have a significantly worse outcome.^3,8-10 In general, patients who are confined to bed tolerate aggressive forms of treatment poorly, have increased morbidity, and rarely attain 2-year disease-free survival. However, patients with poor performance status can often derive significant palliative benefit and prolongation of survival from treatment.

Regardless of stage, the current prognosis for patients with small cell lung cancer is unsatisfactory even though considerable improvements in diagnosis and therapy have been made over the past 10 to 15 years. Therefore, all patients with this type of cancer may appropriately be considered for inclusion in clinical trials at the time of diagnosis.

References:

1. Prasad US, Naylor AR, Walker WS, et al.: Long-term survival after pulmonary resection for small cell carcinoma of the lung. Thorax 44(10): 784-787, 1989.
2. Johnson BE, Grayson J, Makuch RW, et al.: Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal of Clinical Oncology 8(3): 396-401, 1990.
3. Lassen U, Osterlind K, Hansen M, et al.: Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. Journal of Clinical Oncology 13(5): 1215-1220, 1995.
4. Fry WA, Menck HR, Winchester DP: The National Cancer Data Base report on lung cancer. Cancer 77(9): 1947-1955, 1996.
5. Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. Journal of Clinical Oncology 11(2): 336-344, 1993.
6. Johnson BE, Bridges JD, Sobczeck M, et al.: Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. Journal of Clinical Oncology 14(3): 806-813, 1996.
7. Turrisi AT III, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New England Journal of Medicine 340(4): 265-271, 1999.
8. Wolf M, Holle R, Hans K, et al.: Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. British Journal of Cancer 63(6): 986-992, 1991.
9. Rawson NS, Peto J: An overview of prognostic factors in small cell lung cancer: a report from the subcommittee for the management of lung cancer of the United Kingdom Coordinating Committee on Cancer Research. British Journal of Cancer 61(4): 597-604, 1990.
10. Chute JP, Venzon DJ, Hankins L, et al.: Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clinic Proceedings 72(10): 901-912, 1997.

  Back to Content Page                                         Next >>